

Dear

FREEDOM OF INFORMATION – CANCER PRESCRIBING

I write in response to your request for information in relation to cancer prescribing.

Question:

- 1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Answer:
Yes

Question:

- 2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:
 - a. Dostarlimab (Jemperli)
 - b. Dostarlimab (Jemperli) + Chemotherapy
 - c. Hormone therapy (Progesterone or Letrozole) data unavailable
 - d. Lenvatinib + Pembrolizumab (Keytruda + Lenvima)
 - e. Pembrolizumab monotherapy (Keytruda)
 - f. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
 - g. Durvalumab with Platinum-based Chemotherapy
 - h. Pembrolizumab with Platinum-based Chemotherapy
 - i. Any other SACT
 - j. If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for Endometrial cancer

Answer:

a.	8
b.	5<
c.	*requires data linkage

d.	7
e.	8
f.	23
g.	0
h.	0
i.	5<
j.	IV Infusion only

Question:

3. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:
- Dostarlimab (Jemperli) + Chemotherapy
 - Hormone therapy (Progesterone or Letrozole)
 - Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
 - Durvalumab with Platinum-based Chemotherapy
 - Pembrolizumab with Platinum-based Chemotherapy
 - Any other SACT
 - If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for first line Endometrial cancer

Answer:

a.	5<
b.	*requires linkage
c.	17
d.	0
e.	0
f.	9
g.	IV Infusion only

*Please note this is not held in a centrally extractable format. Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

Question:

4. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Answer:

Full Title	Recruited
TroFuse-033, A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (GOG-3119/ENGOT-en29)	5<
OMAHA-015, A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors	0

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
 Executive Director, Nursing
 Cc: Chief Executive